WestEnd Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

WestEnd Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1M	Sell	19,419 -6,194	-24%	-$4.22M	0.27%	40
2026 Q1	$19.8M	Buy	25,613 +25,606	+365,800%	+$19.6M	0.48%	39
2025 Q4	$5.4K	Buy	7 +4	+133%	+$2.72K	﹤0.01%	104
2025 Q3	$1.69K	Sell	3 -1	-25%	-$565	﹤0.01%	175
2025 Q2	$2.1K	Hold	4	–	–	﹤0.01%	142
2025 Q1	$2.54K	Buy	4 +3	+300%	+$2.06K	﹤0.01%	135
2024 Q4	$712	Hold	1	–	–	﹤0.01%	151
2024 Q3	$1.05K	Hold	1	–	–	﹤0.01%	121
2024 Q2	$1.05K	Sell	1 -1	-50%	-$969	﹤0.01%	118
2024 Q1	$1.93K	Hold	2	–	–	﹤0.01%	90
2023 Q4	$1.76K	Hold	2	–	–	﹤0.01%	94
2023 Q3	$1.65K	Buy	+2	New	+$1.57K	﹤0.01%	87
2023 Q1	–	Sell	-1	Closed	-$754	–	118
2022 Q4	$721	Hold	1	–	–	﹤0.01%	121
2022 Q3	$1K	Hold	1	–	–	﹤0.01%	127
2022 Q2	$591	Buy	+1	New	+$650	﹤0.01%	129
2022 Q1	–	Sell	-1	Closed	-$633	–	129
2021 Q4	$631	Buy	+1	New	+$615	﹤0.01%	143
2021 Q3	–	Hold	0	–	–	–	130
2021 Q2	–	Hold	0	–	–	–	134

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

WestEnd Advisors's REGN Position: Q2 2026 in Review

WestEnd Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 24% in Q2 2026, selling an estimated $4.22M and leaving 19,419 shares worth $12.1M. The position accounts for 0.27% of the portfolio, ranked #40.

WestEnd Advisors first reported a position in REGN in Q4 2021 and has held it in 16 quarters since. The position peaked at $19.8M in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

WestEnd Advisors held 19,419 shares of Regeneron Pharmaceuticals worth $12.1M as of Q2 2026.
WestEnd Advisors sold 6,194 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.22M.
Regeneron Pharmaceuticals made up 0.27% of WestEnd Advisors's portfolio in Q2 2026, its #40 holding.
WestEnd Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
WestEnd Advisors's Regeneron Pharmaceuticals position peaked at $19.8M in Q1 2026.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.